How Have Concerns About Power Morcellation Altered U.S. Gynecologic Surgical Practice?

Minimally invasive surgery continues to be widely practiced even in the absence of power morcellation.

The FDA's 2014 warning about possible intraperitoneal dissemination of malignant cells as a consequence of power morcellation during minimally invasive hysterectomy or myomectomy has the potential to alter the practice of gynecologic surgery. In three retrospective studies, researchers sought to determine the impact of this warning on use of minimally invasive approaches (i.e., laparoscopic or vaginal with or without robotic assistance) for hysterectomy and myomectomy.

The first study was a cohort analysis of almost 32,000 hysterectomies performed between 2008 and 2015 for benign disease in women aged ≥18 in an integrated health system in California. During the observation period, rates of minimally invasive hysterectomies rose from 40% to 9…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

How Have Concerns About Power Morcellation Altered U.S. Gynecologic Surgical Practice?

Topics

Reviewing Author